SporeVax

SporeVax is a mucosal vaccine platform developed by SporeGen that utilizes heat-stable bacterial spores, specifically *Bacillus subtilis*, as a delivery vehicle for antigens. The platform is designed for oral or sublingual administration, aiming to induce both mucosal and systemic immunity. A key advantage of the SporeVax technology is its inherent stability at ambient temperatures, which eliminates the requirement for cold-chain storage and distribution. The spores act as a natural adjuvant and protective carrier, allowing the vaccine to survive the harsh environment of the gastrointestinal tract when administered orally. While the platform is positioned for the development of vaccines against various infectious pathogens, specific clinical candidates and their target indications are not currently detailed in a structured pipeline format.

Brand names

SporeVax